Research programme: Down's syndrome therapeutics - Kino Pharma
Latest Information Update: 01 Apr 2021
At a glance
- Originator Kino Pharma
- Class
- Mechanism of Action DYRK kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Down syndrome
Most Recent Events
- 16 Mar 2021 Preclinical trials in Down syndrome in Japan (unspecified route), prior to March 2021 (Kino Pharma pipeline, March 2021)
- 16 Mar 2021 Kino Pharma plans a clinical trial for Down syndrome (Kino Pharma pipeline, March 2021)